Highest-materiality recent filing
Amgen annual meeting elects all 12 directors; shareholder independent-chair proposal rejected
All 12 director nominees elected; Robert Bradway received 390M votes for, 20.5M against.
Amgen CFO Peter Griffith retiring; Thomas Dittrich to succeed September 1, 2026
Peter Griffith retiring as EVP/CFO effective Aug 31, 2026; stays as non-executive EVP through Jan 2027.
Amgen Q1 2026 revenue $8.6B (+6% YoY), Non-GAAP EPS $5.15 (+5% YoY)
Total revenue $8.6B (+6% YoY); product sales grew 4% driven by 9% volume growth.
Amgen EVP and CTO David M. Reese to retire June 30, 2026; roles redistributed
David M. Reese retires as EVP and CTO effective June 30, 2026; responsibilities split among Bradner, Gordon, Griffith starting June 1.
Amgen issues $4.0B in senior notes across four tranches with maturities 2031-2056
Issued $1.0B 4.200% notes due 2031, $1.75B 4.850% notes due 2036, $500M 5.500% notes due 2046, $750M 5.650% notes due 2056.
Amgen Q4 rev +9% to $9.9B; FY rev +10% to $36.8B; GAAP EPS $2.45, non-GAAP $21.84
Q4 total revenues $9.9B (+9% YoY); product sales +7% driven by 10% volume growth.
Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance
Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
Amgen Q3 revenue up 12% to $9.6B, GAAP EPS $5.93, non-GAAP EPS $5.64
Revenue $9.6B (+12% YoY), product sales growth 12% on 14% volume growth, partially offset by 4% lower net price.
Amgen Q2 revenue $9.2B (+9% YoY); GAAP EPS $2.65 (+92%), non-GAAP EPS $6.02 (+21%)
Total revenues $9.2B, up 9% YoY; product sales up 9% on 13% volume growth, partially offset by 3% lower net selling price.
Amgen shareholders elect all 12 director nominees and approve say-on-pay at 2025 annual meeting
All 12 directors elected; CEO Robert A. Bradway received 375.7M for (93.0%) vs 26.4M against.
Amgen Q1 beats: revenue $8.1B (+9%), non-GAAP EPS $4.90 (+24%), FCF $1.0B
GAAP EPS $3.20 vs -$0.21; includes $800M Otezla intangible impairment.
Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)
Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).
Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)
Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.
Amgen Q2 2024 revenue up 20% to $8.4B, but GAAP EPS falls 46% to $1.38
Total revenues $8.4B, up 20% YoY; product sales up 20% (5% ex-Horizon), driven by 26% volume growth.
Amgen stockholders approve 31.3M share increase in equity plan, re-elect all 12 directors
Stockholders approved Second Amended and Restated 2009 Equity Incentive Plan, adding 31,297,000 shares.
Amgen Q1 2024 revenue up 22% to $7.4B; GAAP EPS loss of $0.21 on BeiGene mark-to-market loss
Total revenue $7.4B (+22% YoY); product sales grew 22% driven by 25% volume growth; Horizon contributed $914M.
Amgen Q4 2023 revenue $8.2B (+20% YoY); Non-GAAP EPS $4.71 (+15% YoY)
Fourth quarter total revenue $8.2B, up 20% YoY; product sales grew 20% driven by 23% volume growth.
Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO
James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.
Amgen Q3 revenue $6.9B (+4% YoY); GAAP EPS $3.22 (-19%); Non-GAAP EPS $4.96 (+6%)
Total revenues $6.9B (+4% YoY); product sales +5% on 11% volume growth.
Amgen completes $27.8B acquisition of Horizon Therapeutics at $116.50/share
Paid $26.7B cash for Horizon shares; borrowed $4B under term loan to fund portion of consideration.
Amgen's acquisition of Horizon Therapeutics sanctioned by Irish High Court
Irish High Court sanctioned the scheme of arrangement on October 5, 2023, moving deal closer to completion.
Amgen and Horizon extend acquisition outside date to Dec 12, 2023; Irish court hearing Oct 5
First Extended End Date automatically extended to Second Extended End Date, December 12, 2023.
Amgen clears FTC hurdle for Horizon acquisition; Irish court hearing Oct 5
US District Court dismissed preliminary injunction motion and dissolved TRO on Sept 1, 2023.
Consent order agreement with FTC resolves pending administrative lawsuit related to Amgen's acquisition of Horizon.
Amgen appoints Matthew C. Busch as new Chief Accounting Officer effective Aug 14, 2023
Matthew C. Busch, 49, named VP, Finance and CAO; succeeds Linda H. Louie who moves to VP, Finance.
Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00
Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.
Amgen-Horizon deal TRO extended to Oct 31; FTC injunction hearing set Sept 11
Court granted revised stipulated TRO extending the block on closing to Oct 31, 2023 or 2 business days after ruling on FTC injunction.
All 13 director nominees elected; Greg C. Garland received highest votes against at 48.8M shares.
FTC obtains stipulated TRO blocking Amgen's Horizon acquisition until Sept 15 or court ruling
FTC filed complaint May 16, 2023 in N.D. Illinois seeking to enjoin $27.8B acquisition of Horizon Therapeutics.
FTC sues to block Amgen's Horizon acquisition; Amgen vows to fight
FTC filed complaint in federal court seeking to enjoin acquisition of Horizon Therapeutics.
Amgen Q1 2023: Revenue $6.1B (-2%); GAAP EPS $5.28; non-GAAP EPS $3.98 (-6%)
Total revenues $6.1B (-2% YoY); product sales +2% with 14% volume growth; ex-U.S. volume grew 22%.
Amgen terminates $28.5B Horizon bridge facility, enters new $4B revolver
Bridge credit facility (originally $28.5B) for Horizon Therapeutics acquisition terminated March 9, 2023 after reductions from $4B term loan and $23.8B senior note proceeds.
Amgen issues $24B in senior notes to fund Horizon Therapeutics acquisition
Issued $24B aggregate principal across eight tranches (2025-2063 maturities) with rates 5.150%-5.750%.
Amgen issues $24B of senior notes across eight tranches from 2025 to 2063
$2B of 5.250% notes due 2025, $1.5B of 5.507% notes due 2026, $3.75B of 5.150% notes due 2028.
Amgen posts flat Q4 revenue $6.8B, GAAP EPS down 11%; FTC extends HSR review for Horizon deal
GAAP EPS $3.00 (down 11% YoY); non-GAAP EPS $4.09 (down 7% YoY).
Amgen enters $4B term loan facility for Horizon acquisition, Dec 22, 2022
Term Loan Credit Agreement provides a $2B 18-month tranche and a $2B 3-year tranche, dated Dec 22, 2022.
Amgen to acquire Horizon Therapeutics for $116.50/share; $28.5B bridge facility arranged
Cash offer of $116.50 per Horizon share; transaction unanimously recommended by Horizon Board.
Amgen confirms potential all-cash offer for Horizon Therapeutics
Amgen states any offer for Horizon will be solely in cash.
GAAP EPS $3.98 (up from $3.31); non-GAAP EPS $4.70 (up from $4.08).
Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio
Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.
Amgen issues $3B in senior notes across three tranches with maturities 2029-2053
Issued $1.25B of 4.050% Senior Notes due 2029, $750M of 4.200% due 2033, and $1.0B of 4.875% due 2053.
Amgen Q2 2022: GAAP EPS $2.45, revenue $6.6B; guidance updated; non-GAAP policy change
Total revenues $6.6B (+1% YoY); product sales +3% driven by Repatha, Prolia, LUMAKRAS, EVENITY.
Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS
Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.
Amgen appoints Michael V. Drake to Board of Directors effective August 3, 2022
Dr. Drake is president of the University of California, with medical and academic leadership background.
Amgen shareholders elect all 12 director nominees, approve say-on-pay, ratify EY auditor
All 12 director nominees elected; highest against votes: R. Sugar (66.9M) and R. Eckert (62.8M).
Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide
Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.
Amgen enters $6B accelerated share repurchase agreements; initial delivery of ~23.3M shares
Entered ASR agreements with Bank of America, Morgan Stanley, and Goldman Sachs to repurchase up to $6B of common stock.
Amgen issues $4B of senior notes across four tranches with maturities to 2062
Issued $750M 3.000% notes due 2029, $1B 3.350% notes due 2032, $1B 4.200% notes due 2052, $1.25B 4.400% notes due 2062.
Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)
Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.
Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing
Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.
On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.
Effective September 1, 2026, he will serve as Executive Vice President and Chief Financial Officer of the Company.
James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.
David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.
On August 1, 2023, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Matthew C. Busch, age 49, to serve as the Company’s Vice President, Finance and Chief Accounting Officer (“CAO”), effective August 14, 2023.
Linda H. Louie, the Company’s current CAO, has served in this role since July 2020, and effective August 14, 2023, as part of the Company’s leadership development activities, Ms. Louie will move to the role of the Company’s Vice President, Finance, with responsibility for corporate financial planning and analysis, and will step down as the Company’s Chief Accounting Officer.
On August 3, 2022, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Michael V. Drake as a director of the Company, effective immediately.
On July 29, 2021, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed S. Omar Ishrak as a director of the Company, effective immediately.
Max materiality 0.90 · Median 0.75 · Most common event earnings